A phase II clinical trial of HER-Vaxx (IMU - 131), a therapeutic B cell epitope vaccine for patients with advanced HER2-overexpressing gastric cancer, demonstrated that vaccine-induced HER2-specific antibody responses were significantly associated with tumor regression and improved immunologic function. The addition of chemotherapy further enhanced therapeutic efficacy. This evidence concerns the gene ERBB2 and gastric cancer.